Spring naar inhoud

Research and Development

R&D at PARTREC

The PARTREC research and development program covers a full range of work needed to convert fundamental physics and biology knowledge into clinically useful tools. Therefore, it has been focused on answering the physics-related needs of the radiation biology program and novel radiotherapy technology development in terms of hardware and software in collaboration with academic and industrial partners.

To meet the requirements of future experiments for internal and external users developments related to the beam (for ex. elements related to the beamline, FLASH mode, etc.) and upgrade of the irradiation facilities have been undertaken (for ex. infrastructure for high precision biology experiments).

The biology research continued to be directed to and translated into prediction, prevention and treatment of normal tissue side effects. The FLASH program has been added for Physics, Biology and Radiation Oncology research while new venues in Nuclear Medicine Physics, such as Theranostics, have been initiated in collaboration with UMCG Nuclear Medicine and Shine. All research should be aimed to produce high-impact results and publications both from a scientific and a societal point of view.

4.1 Research Groups from PARTREC

4.1.1 Group leader: Alexander Gerbershagen

Group name: Accelerator and Radiation Physics 

PARTREC operates a superconducting cyclotron AGOR, providing proton and ion test beams to several test beam rooms. In addition to operating, maintaining and upgrading the facility, the Accelerator and Radiation Physics Team is working on further development of the accelerator system and its components for boosting of beam intensity and extension of accelerated particle types, as well as on advanced beam control, beam and patient diagnostics and dosimetry.

Topics within the research line:

  • Development of novel dose delivery methods and dose application techniques
  • Increase of the beam intensity for FLASH irradiations
  • Development of dosimetry and dose control for irradiations with ultra-high dose rates
  • Extension of the ion cocktail to heavier ions
  • Production of radioisotopes for nuclear medicine
  • Combination of boron proton capture with FLASH irradiation

4.1.2 Group leader: Marco Schippers

Group name: Accelerator Physics

Research is focused on the optimization and development of new technologies for the use of the beams from AGOR. Beam development procedures are improved by developing and implementing standardized procedures. Driven by ongoing scientific projects, investigations are performed on methods of beam delivery under specific conditions.

4.1.3 Group leader: Peter Dendooven

Group name: In vivo verification of proton therapy

We investigate positron emission imaging for real-time dose delivery verification during proton therapy. We focus on the translation of nitrogen-12 imaging to the clinic, and on combining this with proton radiography.

4.1.4 Group leader: Sytze Brandenburg (Emeritus)

Group name: In vivo verification of proton therapy

We primarily focus on advancing particle radiotherapy. Our expertise spans accelerator physics and technology, radiation physics, and medical physics. We lead projects in developing image-guided preclinical particle therapy research and supervise technical and engineering staff in accelerator R&D. Our work in radiation physics is dedicated to enhancing particle therapy, aiming to improve its efficacy and precision in medical treatments.

4.2 Research Groups associated with PARTREC

4.2.1 Group leader: Julia Even

Group name: Nuclear chemistry & physics

Our research focuses on exotic, atomic nuclei far away from the valley of stability. In particular, we are interested in heavy, neutron-rich nuclei which are relevant for the synthesis processes of heavy elements in our universe. At PARTREC we are building a new experiment called NEXT to study Neutron-rich, heavy, EXOTIC nuclei produced in multinucleon Transfer reactions.

4.2.2 Group leader: Lara Barazzuol

Group name: Radiation-induced adverse effects in the brain

When using radiotherapy in the treatment of brain tumours, damage to normal brain tissue is an unavoidable side effect. Lara Barazzuol’s research group aims to understand the underlying biological and molecular mechanisms of radiotherapy-induced neurocognitive dysfunction.

4.2.3 Group leader: Peter van Luijk

Group name: Translational normal tissue radiobiology

At the interface between lab and clinic, we use animal models to elucidate processes leading to normal tissue damage and translate this knowledge into clinically applicable strategies to reduce the side effects of radiotherapy.These strategies are subsequently tested in clinical studies.

4.2.4 Group leader: Rob Coppes

Group name: Effects of radiation on normal tissues

Our lab is investigating how radiation-induced environmental changes influence the regenerative response of tissues:

  • Our main goal is to understand the molecular mechanism related to stem cell functioning after irradiation.
  • We aim to unravel the processes that inhibit stem cell functioning after irradiation using in vivo and in vitro organoid models.
  • We dissect changes in gene expression of cells in the tissue stem cell niche post-irradiation to study the interaction between stem cells and their surrounding cells to find tools to optimize regeneration.
  • With this knowledge we aim to understand how to optimize stem cell therapies to ameliorate radiation-induced normal tissue side effects

4.2.5 Group leader: Stefan Both

Group name: Instrumentation and FLASH Dosimetry

Our research is focused on proton radiography measurements and interpretation towards clinical translation for static and moving targets. Currently materialized in two clinical programs in Head and Neck Cancer and Lung.

Flash research is focused on small animal high-precision irradiation employing conformal flash and experimental setup optimization in radiobiology. The first experiments were conducted in organoids and mice to follow.

4.3 Research Collaborations

Alex Gerbershagen

Beam Physics:

  • GaToroid(with CERN and Oxford University)
  • Statis Gantry (with MGH, Harvard Medical School and RCNP (Osaka University))
  • CLEAR/FLASH VHEE (with CERN and Oxford University)
  • AWAKE(with CERN)
  • Experiments and detector technology
  • AMBER
  • NA60+
  • SHADOWS
  • HIKE

Networks we are in:

  • Next Ion Medical Machine Study (NIMMS)
  • Enlight
  • Joint Universities Accelerator School (JUAS)
  • The European Committee for Future Accelerators
  • (ECFA)Detector R&D Roadmap Process Group
  • COST Mission
  • MultIChem - Multiscale Irradiation and Chemistry Driven Processes
  • Member of FLUKA software collaboration
  • Member of Collaboration Board of AMBER experiment at CERN
  • Member of Next Ion Medical Machine Study (NIMMS) collaboration
  • Membership in the Advisory Board of Joint Universities Accelerator School (JUAS)
  • Member of Laser-hybrid Accelerator for Radiobiological Applications (LhARA) peer-group consultation team
  • Francesco Romano: Member of the International Geant4 Collaboration

Industrial:

Julia Even

  • Superheavy element physics group at GSI Helmholtz Center for Heavy Ion Research, Darmstadt, Germany.
  • Superheavy element physics group at Helmholtz-Institute Mainz, Mainz, Germany
  • Superheavy element physics group at the Johannes Gutenberg University of Mainz, Mainz, Germany
  • Accelerator Laboratory, University of Jyväskylä, Jyväskylä, Finland
  • Darmstadt’s MR ToF Collaboration (DA’s MR-ToF): Technical University of Darmstadt(Germany), the University of Greifswald (Germany), the University of Groningen, the University of Manchester (UK), the Massachusetts Institute of Technology(U.S.A.), the Johannes Gutenberg University Mainz (Germany), and the University of Innsbruck (Austria).
  • Pre-enrichment of calcium: Radboud University, Nijmegen (the Netherlands)
  • ENW-XL: University of Amsterdam, Nikhef Amsterdam, University of Utrecht, University of Groningen, University of Maastricht

Lara Barazzuol

Academic:

  • Martin McCabe, University of Manchester, UK.
  • Thomas Merchant, St. Jude Children's Research Hospital, US.
  • Ricardo M. Papaléo, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Brazil.
  • Theodossis Theodossiou, University of Oslo, Norway.

Industrial:

  • IBA (Ion Beam Applications SA).

Peter Dendooven

Academic:

  • GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany

Industrial:

  • Siemens Healthineers
  • Raysearch Laboratories, Stockholm, Sweden

Sytze Brandenburg

Academic:

  • UMCG NGMB: development of radionuclide production and associated pre-clinical research at PARTREC

Industrial:

  • SHINE: development of radionuclide production at PARTREC
  • EVIDENSIA: development of a small animal proton therapy clinic at PARTREC

4.4 Scientific Highlights

Alexander Gerbershagen

  • Completion of the Long Shutdown and solution to the long-standing problems with cryogenic system. Restart of routine operation in Q3.
  • SARRP has been delivered and installed at PARTREC. First beam has been sent in first beam in IMPACT beam line on October 10th. IMPACT is a KWF-sponsored novel beamline with unique capabilities for small animal irradiations.
  • Implementation of remote access capability in the framework of EUROLABS program.
  • Upgrade of Germanium detectors executed. The detectors are used for the nuclear preparedness program and for the isotope production research.

Sytze Brandenburg

  • We completed the installation of the IMPACT research infrastructure and performed first commissioning experiment

4.5 Research Projects and Funding

Each year our researchers apply for and receive funding from various research funding agencies across the world. Below we list the projects that received funding and started with a starting date in 2024. Note that one or more of these projects may have been awarded with an acceptance letter in the year before. The starting date is when both the UMCG and the funding agency agree that the Grant Agreement enters into force.

Projects awarded to PARTREC/UMCG with starting date in 2024

# Groupleader Funding body Project title Funding awarded to PARTREC/ UMCG
1 Alexander Gerbershagen Stichting Steunfonds UMCG Fast Degrader for FLASH Proton Therapy Irradiations € 58.522
2 Alexander Gerbershagen, Brian Jones EU RIANA: Research Infrastructure Access in NAnoscience & nanotechnology € 49.725
3 Alexander Gerbershagen,
Lara Barazzuol
EU NuCapCure: Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis € 756.256
4 Lara Barazzuol SU2C-CRUK BRAINatomy 2: Optimizing cognition after brain radiotherapy € 1.100.445
5 Peter Dendooven KWF Continual personalised quality control during proton therapy (COPCOPT) € 112.530
6 Peter van Luijk,
Julia Wiedemann,
Rob Coppes
Dutch Cancer Society From proof-of-concept to a safe and effective intervention for cardiopulmonary side effects of thoracic radiotherapy (AVERTmore) € 858.229
7 Stefan Both RaySearch / PPP Autoplanning static and moving targets (AUTOPLANNING) € 855.342
      TOTAL € 3.791.049